Home > News > Starpharma gets US nod to work on HIV gel
November 19th, 2003
Starpharma gets US nod to work on HIV gel
Abstract:
Biotech play Starpharma is five years away from the full commercialisation of its topical HIV/AIDS protection product, chairman Peter Bartels told shareholders yesterday. Speaking at the annual meeting, he said the company recently started human trials in Adelaide of its VivaGel product after approval from the US Federal Drug Administration. He said Starpharma had chosen the more difficult path of seeking clearance for the gel in the US rather than Australia as success overseas would deliver greater kudos and earnings.
Source:
The Age
Bookmark:
| Related News Press |
Nanomedicine
A fundamentally new therapeutic approach to cystic fibrosis: Nanobody repairs cellular defect April 17th, 2026
New molecular technology targets tumors and simultaneously silences two ‘undruggable’ cancer genes August 8th, 2025
New imaging approach transforms study of bacterial biofilms August 8th, 2025
Electrifying results shed light on graphene foam as a potential material for lab grown cartilage June 6th, 2025
 |
||
 |
||
| The latest news from around the world, FREE | ||
 |
||
|
|
||
| Premium Products | ||
 |
||
|
Only the news you want to read!
Learn More |
||
 |
||
|
Full-service, expert consulting
Learn More |
||
|
|
||